In this study, the authors apply a computer-based strategy to screen thousands of small-molecule, nonpeptidic organic compounds in the Available Chemicals Directory database and to select a series of potential candidates as ligands of the proposed CD4 D1 surface pocket. Then, several cell-based models are used to determine the actual biological functions of these compounds. A small molecule designated A5 (N-((pyridine-4-yl)methylene)thiophene-2-carbohydrazide) was obtained by a virtual screening followed by 3 cell-based functional assays. The results show that A5 could specifically block the CD4-major histocompatibility complex II binding in a rosetting assay, inhibit the mixed lymphocyte reaction-induced T-cell proliferation in a concentration-dependent manner, and reduce the PMA plus ionomycin-stimulated interleukin-2 secretion from peripheral blood mononuclear cells. (Journal of Biomolecular Screening 2007:800-808) 
INTRODUCTION
I T IS WELL KNOWN that protein-protein interactions play an important role in a wide range of physiological and pathological processes. The interactions between proteins generally involve large interfaces with many intermolecular contacts. 1, 2 Recently, studies indicate that proteins may actually interact through small surface-binding epitopes, such as in the cases of the human growth hormone-receptor complex and the erythropoietin-receptor complex. An intriguing possibility is thus raised that the rational design of small-molecule inhibitors of these surface-binding pockets might lead to the development of novel potent antagonists either in peptide form or, more preferably, in nonpeptide form.
CD4 is a cell-surface glycoprotein that participates in molecular complexes involved in both T-cell development and antigen recognition by T cells. It contains a large extracellular portion, a membrane-spanning segment, and a short cytoplasmic tail. 3 The extracellular part of CD4 consists of 4 tandem immunoglobulinlike domains (D1-D4), joined in an extended, rodlike structure. 4, 5 The CD4 molecule is expressed on most thymocytes and on the subset of peripheral T lymphocytes, which includes helper T cells and class II major histocompatibility complex (MHC)-specific cytotoxic T cells. The interaction between CD4 and MHC II proteins is important for triggering signal transduction through the T-cell receptor by the class II MHC-presented antigen, which is critical for both thymocyte differentiation and T-cell activation. Once activated, CD4 + helper T cells stimulate B-cell antibody production and cytolytic T-cell generation, thereby regulating the induction of the immune responses. Convergent studies have suggested that CD4 + T cells participate in the pathogenesis of a number of immune-based human conditions, including autoimmune diseases (such as allergic encephalomyelitis, multiple sclerosis, and rheumatoid arthritis) and transplantation rejections directed to the allogeneic MHC class II antigens. Therefore, development of methods to block the CD4-MHC II interaction might lead to an important new class of inhibitors, which could potentially block the undesirable activation of CD4 + T cells and thus serve as effective immunosuppressive agents.
A large body of experimental evidence has identified that residues in the membrane-distal D1 and D2 of CD4 are involved in its interaction with class II MHC molecules. [6] [7] [8] Most of these residues are in D1. Overall, there are 5 main interaction elements on the N-terminal domain of CD4 (D1) for its binding to the 2 membrane-proximal domains (α2 and β2) of class II MHC proteins: Phe-43, the C″ strand, the FG loop, the CC′ loop, and the short α-helical segment between β strands D and E. Although the general applicability of the hypothesis for rational drug design targeting protein-protein surface-binding epitopes remains to be tested, many efforts have been made to develop small-molecule mimics or inhibitors of these respective CD4 surface-binding pockets [9] [10] [11] [12] for potential antagonists in stable CD4-MHC class II binding.
In this study, based on the 3-D complex structure of CD4 and MHC class II, a series of nonpeptide small molecules that possessed a potential blocking function to CD4 D1 were selected from the Available Chemicals Directory (ACD; Molecular Design Limited, San Leandro, CA) database using a computer-aided screening approach. To further evaluate the binding mode, the 3-D complex between the potential inhibitors and CD4 was modeled using a molecular docking method, and the binding energy was calculated. One of the inhibitors, A5, was obtained and shown to bind to several important sites in the DE helix and C′C″ loop of CD4 molecules involved in the CD4-MHC II interaction. Then, 3 cell-based assays were tested to determine the actual biological function of A5. The results demonstrated that A5 could specifically block the stable CD4-MHC class II molecule binding and inhibit the CD4-dependent T-cell proliferation and interleukin (IL)-2 secretion.
MATERIALS AND METHODS

Antibodies, cell lines, and reagents
HEK293 (ATCC, CRL-1573), a human embryonic kidney cell line, was cultured in DMEM/F12 (1:1) medium containing 10% fetal bovine serum. Cells of HPB-ALL or Raji were maintained at 37 °C and 5% CO 2 in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum. Anti-CD4 mAbs used were Leu-3a (IgG1; Becton Dickinson, San Jose, CA) and PElabeled Leu-3a (Becton Dickinson). PE-labeled mAb L243 (IgG2a) recognizing a conformational determinant on the DR heterodimer was purchased from BioLegend (San Diego, CA). The vector pEGFP-N1 was purchased from Clontech (Mountain View, CA). All the small-molecule compounds tested were provided by Professor Song Li and his laboratory. These compounds were prepared as 10 -1 M stocks in DMSO, which were then serially diluted in culture medium to the indicated concentrations just before use. The concentration of DMSO was at or below 0.1%, which alone has no effect on the cells.
Theoretically screening small molecules
The complex structure reveals that the CD4 D1 is directed toward and reaches into both the α2 and β2 domains of class II MHC molecules. The CD4 D1 domain contains an AGFCC′C″ strand, which is bound by FG (CDR3), CC′ and C′C″ loops (CDR2), and a BED strand. In this study, the CD4 D1 domain, with multiple faces for binding to class II MHC molecules, was used as a receptor for DOCK3.5 ligand docking. DOCK3.5 is an automatic computerized method to screen small-molecule databases for possible ligands that could bind to a given receptor. 13 The binding of the respective organic ligand to the different CD4 D1 surface pocket was evaluated both by shape complementarity and by force-field energy. The ACD (Molecular Design Limited) was chosen as the small-molecule database to be screened for potential ligands. Following a modified procedure of Ring et al., 14 1000 molecules with the best shape complementarity scores and 1000 molecules with the best force-field scores were selected from a DOCK3.5 screening. The resulting 2000 compounds were then visually screened 3 times independently in the context of the CD4 D1 surface-binding pocket using the molecular display software InsightII. In the 1st visual screening, no compound was selected in an attempt to get acquainted with the ligand-receptor complex. In the 2nd and 3rd screenings, an effort was made to choose a set of diverse compounds that possessed distinctive chemical structures, receptor-binding modes, and electrostatic and shape complementarities. Ultimately, 51 compounds were chosen for synthesizing and then for testing in cellular adhesion and mixed lymphocyte reaction (MLR) assays. The overall work flow outlining the major points in this computer-aided screening for potential compounds is shown in Figure 1 (Theory section).
Molecular docking
Based on the crystal structure of CD4 (PDB code: 3CD4), the 3-D theoretical structure of CD4 was obtained using the HOMOLOGY module of the InsightII 2000 software (MSI, San Diego, CA). Dealing with the CVFF and Amber force field, the structure of CD4 was optimized using the Discover_3 module of the InsightII 2000 software.
Considering the surface electrostatic distribution and structural character, the complex of CD4 and A5 was obtained using the Docking module of the InsightII 2000 software. The refinement of the initial complex model was carried out by using molecular mechanics and molecular dynamics techniques. The Discover_3 program was used to generate the low-energy conformation of the complex. An approximate solvent screening effect was introduced by use of the distance-dependent dielectric term in the electrostatic potential term. The system was subjected to 100 ps of molecular dynamics at 300 K, and configurations were obtained through quenching of trajectories at 5-ps intervals.
Cell adhesion assay (rosette formation assay)
HEK293 cells that stably transduced with the EGFP-CD4 chimera 15 were plated in 35-mm tissue culture dishes at a density of 1 × 10 5 cells per dish in DMEM-F12 medium containing 10% fetal calf serum (FCS) and cultivated for 16 to 24 h. Raji B cells (1-2 × 10 7 cells), expressing MHC class II molecules, were added in 1 ml of RPMI 1640 medium containing 10% FCS. The cell mixture was incubated at 37 °C for 1 h in the presence or absence of an organic compound tested at appropriate concentrations and then washed extensively by RPMI 1640 complete medium 3 to 5 times to remove the nonadherent Raji B cells. Rosette formation (3-5 or more Raji B cells attached to the surface of CD4transfected cells) was observed under inverted light microscopy. Inhibition of rosette formation was determined by the number of rosettes obtained in the presence of an organic compound relative to the number of rosettes in the positive control. HEK293 cells stably transfected with pEGFP-N1 vector alone served as a negative control, which showed no rosette formation.
Mixed leukocyte reaction
In a 96-well, flat-bottom microplate (Nunc, Roskilde, Denmark), 1 × 10 5 responder peripheral blood mononuclear cells (PBMCs) were cultured with 2 × 10 5 irradiated (30 Gy) stimulator PBMCs/well in a final volume of 100 µl and incubated for 6 days at 37 °C, 5% CO 2 . Various small-molecule compounds (including DMSO serving as a negative control) were added at appropriate concentrations (at final concentrations of 0 µM, 1 µM, 10 µM, and 100 µM, respectively) immediately after the cells were plated. Proliferation was determined by the addition of 1 µCi [ 3 H]thymidine per well (New England Nuclear, Boston, MA) during the last 16 h of the culture period and subsequent measurement of incorporated radioactivity in a liquid scintillation counter (PerkinElmer Life Sciences, Boston, MA). All experiments were performed in quadruplicate, and the results were expressed as ∆cpm (experimental minus background) ± SEM. Background cultures were set up using syngeneic stimulator cells. The inhibition percentage rate was calculated as the following formula: inhibition rate % = (1 -% cells treated by tested compounds/% cells untreated) × 100.
Intracellular IL-2 staining for flow cytometric analysis
PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation and resuspended (1 × 10 6 /ml) in complete culture medium consisting of RPMI 1640 medium supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 25 mM HEPES buffer, 50 U/ml penicillin, and 50 mg/ml streptomycin (all from Gibco, Carlsbad, CA). For intracellular cytokine evaluation, PBMCs were placed in 24-well plates (Costar) in a volume of 1 ml per well and incubated for 5 h at 37 °C with 20 ng phorbol myristate acetate per milliliter (cat. no. P8139; Sigma, St. Louis, MO) and 1 µg of ionomycin per milliliter (cat. no. I0634; Sigma) to stimulate cytokine production, in the presence or absence of the small-molecule compounds tested at 100 µM. In all cases, Golgistop (0.7 µl/ml/well; BD Biosciences Pharmingen, Franklin Lakes, NJ) was added to the PBMC cultures from the beginning to inhibit cytokine secretion. The percentage of cells positive for intracytoplasmic IL-2 using a PE-conjugated antibody specific to IL-2 was quantitated by fluorescence-activated cell sorting analysis in accordance with the guidelines provided by the manufacturer (Cytofix/Cytoperm™ Plus [with Golgistop™] kit, cat. no. 554715; BD, San Diego, CA). Lymphocytes were gated for analysis based on light-scattering properties and on CD3 staining. A total of 20,000 events were acquired (data of 1000 lymphocytes were collected).
RESULTS AND DISCUSSION
Virtual screening of small molecules
Previous studies have identified that a large surface area of the CD4 D1 domain, involving Phe-43, the C″ strand, the FG loop, the CC′ loop, and the short α-helical segment between β strands D and E, is important in stable CD4-MHC class II interaction. Therefore, compounds targeted to 1 or more of these vital contacting epitopes would be expected to function as inhibitors of CD4-MHC class II binding and thus CD4 + T-cell-mediated responses. In this regard, several potent inhibitory molecules, including peptides and nonpeptidic organic compounds, have been synthesized and analyzed. [9] [10] [11] [12] These CD4 inhibitors were demonstrated to effectively block stable CD4-MHC class II molecule binding and thus block CD4-mediated immune responses. In this work, we applied the computational screening approach to search thousands of nonpeptidic organic compounds in the ACD database (Molecular Design Limited) for potential ligands of CD4 D1, based on the structure of the identified surface-binding pocket of CD4 D1 spanning multiple faces. This screening selected 51 compounds to be synthesized, and they were tested in actual biological assays. Among them, A5 was shown to have some inhibitory activities.
The 3-D complex structure suggested that A5 recognizes the sites in both the DE and C′C″ loops of CD4, which are thought to be critical for CD4-MHC II binding. This recognition is different from J2, another potential inhibitor of CD4 D1 reported in our previous work, that binds to the surface pocket of the CD4 D1 domain formed by the CC′ and FG loops. As shown in Figure 2B -c, the phenyl ring of A5 contacts with the Leu61, Trp62, and Arg58 sites on CD4 D1 to form a hydrophobic interaction between these 2 molecules. The functional group -C = N-NH-of A5 and the lateral face of CD4 D1, involving Ser60 and Asp63 in the DE helix and Ser42 in the C′C″ loop, meet to form intermolecular hydrogen bonds. The interaction energy between A5 and CD4 was -81.27 Kcal/mol.
A5 inhibited rosette formation
Considering the coverage of several major contacting sites for CD4 binding to class II MHC proteins by A5 in the docking model, including Trp62, which is a strut that supports the projecting C′C″ turn, as well as Ser60 and Asp63, which are thought to form hydrophilic contacts of CD4 with class II MHC α chain proteins, we proposed that A5 could block the CD4-MHC II interaction and thus inhibit the CD4 + T-cell activation-mediated responses. To test this hypothesis, CD4-MHC class II binding studies, using a cell rosetting assay, were performed. Importantly, a stable cell-cell binding model between HEK293/CD4 cells and MHC class II + Raji B lymphoid cells was established in our work. 15 As shown in Figure 3A -a, coincubation of these 2 cell lines resulted in rosette formation. HEK293/CD4 cells attached with 3 or more Raji cells were considered to be rosettes (Fig. 3A-b) . In contrast, HEK293 cells stably transduced with the mock vector alone exhibited no adhesion. Interestingly, the abrogation of the resulting rosettes was observed upon addition of A5. It was shown that A5 had a reproducible inhibitory effect on the HEK293/CD4-Raji cells binding in a concentration-dependent manner. The maximal inhibition rate was as much as 39% at 100 µM (Fig. 3B) , whereas the compounds control C5 at the same concentration could inhibit only 10% of the rosette formation. 
A5 inhibited in vitro MLRs
Next, A5 was tested in an in vitro MLR assay. First, to exclude the toxic effect of A5 on cell proliferation, 2 human cell lines, HPB-ALL and Raji, as well as human PBMCs were grown for 24 or 48 h either in the presence or absence of A5. No inhibition of cell proliferation was observed in all of these cells with A5 treatment (data not shown), indicating that A5 had no cytotoxicity effect. Then, the CD4-dependent human MLR proliferation assays were conducted. The results shown in Figure 4A demonstrated that A5 could inhibit the MLRinduced T-cell proliferation in a dose-dependent manner. The inhibition percentage was 11.12% at 1 µM, 35.69% at 10 µM, and 49.3% at 100 µM, respectively, whereas DMSO addition as the negative control had no substantial effect and C5 as the compounds' control could inhibit the T-cell proliferation by only 10.03%, even at the highest concentration of 100 µM.
A5 inhibited IL-2 production
Finally, the levels of IL-2 in the PBMC cultures stimulated by PMA plus ionomycin with or without 100 µM A5 treatment were measured because the production of IL-2 is considered to be a key event in the initial activation of CD4 + T cells. The results are shown in Figure 4B . A significant reduction of the amount of IL-2 released in the intracellular compartment was observed upon addition of A5 (100 µM). On average, the inhibition rate was about 66%. By contrast, C5 could inhibit the IL-2 production by only 38% in the same condition.
More important, in vivo experiments have been conducted to determine the immunosuppressive activity of A5 in 4 murine models of transplantation rejections: bone marrow, skin, islet, and corneal. 16 Until now, results have shown that A5 possesses some immunosuppressive activity in vivo. All these desirable immunosuppressive activities of A5 imply its potential as a promising lead compound for the development of new immunosuppressants in the treatment of transplant rejections and other CD4 + T cell-related diseases. With this aim, further studies are under way to reconstruct A5 by medicinal chemistry technique and molecular modeling method for analogs with higher affinity and better clinical therapeutic properties.
In summary, the data in this work indicate a paradigm for the inhibitor screening of many Ig-related protein structures and interactions. The overall procedure is shown in Figure 1 . This strategy of screening by computer, obtaining candidates, testing actual function, and gaining 1st-generation leads provides an efficient method for the initial screening of a large database of compounds for selecting a small group of possible candidates and then actual biological testing using 3 cell-based screening models to identify potential lead compounds, thus representing a valuable complement to traditional experimental approaches.
